Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia

Molecular Therapy

Volumn 23, Issue 9, 2015, Pages 1423-1433

  Banin, Eyal ^a   Gootwine, Elisha ^b   Obolensky, Alexey ^a   Ezra Elia, Raaya ^c   Ejzenberg, Ayala ^a   Zelinger, Lina ^a   Honig, Hen ^b   Rosov, Alexander ^b   Yamin, Esther ^a   Sharon, Dror ^a   Averbukh, Edward ^a   Hauswirth, William W ^d   Ofri, Ron ^c  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b VOLCANI CENTER   (Israel)

^c HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CNGA3 PROTEIN; CYCLIC NUCLEOTIDE GATED CHANNEL; MESSENGER RNA; OPSIN; PARVOVIRUS VECTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR; CNGA3 GENE; COLOR BLINDNESS; CONTROLLED STUDY; ELECTRORETINOGRAPHY; GENE; GENE EXPRESSION; GENE THERAPY; GENETIC TRANSFECTION; IMMUNOHISTOCHEMISTRY; NONHUMAN; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; RETINA; RETINA CONE; VISION; ADMINISTRATION AND DOSAGE; ANIMAL; COLOR VISION DEFECTS; DEPENDOPARVOVIRUS; DISEASE MODEL; FEMALE; GENE VECTOR; GENETICS; HOMOZYGOTE; HUMAN; INTRAOCULAR DRUG ADMINISTRATION; MALE; MAZE TEST; METABOLISM; MOUSE; MUTATION; PATHOPHYSIOLOGY; PROCEDURES; REPORTER GENE; SHEEP;

ANIMALS; COLOR VISION DEFECTS; CYCLIC NUCLEOTIDE-GATED CATION CHANNELS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; ELECTRORETINOGRAPHY; FEMALE; GENE EXPRESSION; GENES, REPORTER; GENETIC THERAPY; GENETIC VECTORS; HOMOZYGOTE; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MAZE LEARNING; MICE; MUTATION; RETINA; RNA, MESSENGER; SHEEP; VISION, OCULAR;

EID: 84940719490     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.114     Document Type: Article

References (63)

1. Roosing, S, Thiadens, AA, Hoyng, CB, Klaver, CC, den Hollander, AI and Cremers, FP (2014). Causes and consequences of inherited cone disorders. Prog Retin Eye Res 42: 1-26.
2. Simunovic, MP and Moore, AT (1998). The cone dystrophies. Eye (Lond) 12 (Pt 3b): 553-565.
3. Kohl, S, Marx, T, Giddings, I, Jägle, H, Jacobson, SG, Apfelstedt-Sylla, E et al. (1998). Total colourblindness is caused by mutations in the gene encoding the alpha-subunit of the cone photoreceptor cGMP-gated cation channel. Nat Genet 19: 257-259.
4. Wissinger, B, Gamer, D, Jägle, H, Giorda, R, Marx, T, Mayer, S et al. (2001). CNGA3 mutations in hereditary cone photoreceptor disorders. Am J Hum Genet 69: 722-737.
5. Winick, JD, Blundell, ML, Galke, BL, Salam, AA, Leal, SM and Karayiorgou, M (1999). Homozygosity mapping of the Achromatopsia locus in the Pingelapese. Am J Hum Genet 64: 1679-1685.
6. Kohl, S, Baumann, B, Broghammer, M, Jägle, H, Sieving, P, Kellner, U et al. (2000). Mutations in the CNGB3 gene encoding the beta-subunit of the cone photoreceptor cGMP-gated channel are responsible for achromatopsia (ACHM3) linked to chromosome 8q21. Hum Mol Genet 9: 2107-2116.
7. Kohl, S, Varsanyi, B, Antunes, GA, Baumann, B, Hoyng, CB, Jägle, H et al. (2005). CNGB3 mutations account for 50% of all cases with autosomal recessive achromatopsia. Eur J Hum Genet 13: 302-308.
8. Thiadens, AA, Slingerland, NW, Roosing, S, van Schooneveld, MJ, van Lith-Verhoeven, JJ, van Moll-Ramirez, N et al. (2009). Genetic etiology and clinical consequences of complete and incomplete achromatopsia. Ophthalmology 116: 1984-9. e1.
9. Zelinger, L, Cideciyan, AV, Kohl, S, Schwartz, SB, Rosenmann, A, Eli, D et al. (2015). Genetics and Disease Expression in the CNGA3 Form of Achromatopsia: Steps on the Path to Gene Therapy. Ophthalmology 122: 997-1007.
10. Li, S, Huang, L, Xiao, X, Jia, X, Guo, X and Zhang, Q (2014). Identification of CNGA3 mutations in 46 families: common cause of achromatopsia and cone-rod dystrophies in Chinese patients. JAMA Ophthalmol 132: 1076-1083.
11. Liang, X, Dong, F, Li, H, Li, H, Yang, L and Sui, R (2015). Novel CNGA3 mutations in Chinese patients with achromatopsia. Br J Ophthalmol 99: 571-576.
12. Kohl, S, Baumann, B, Rosenberg, T, Kellner, U, Lorenz, B, Vadalà, M et al. (2002). Mutations in the cone photoreceptor G-protein alpha-subunit gene GNAT2 in patients with achromatopsia. Am J Hum Genet 71: 422-425.
13. Thiadens, AA, den Hollander, AI, Roosing, S, Nabuurs, SB, Zekveld-Vroon, RC, Collin, RW et al. (2009). Homozygosity mapping reveals PDE6C mutations in patients with early-onset cone photoreceptor disorders. Am J Hum Genet 85: 240-247.
14. Kohl, S, Coppieters, F, Meire, F, Schaich, S, Roosing, S, Brennenstuhl, C et al. ; European Retinal Disease Consortium. (2012). A nonsense mutation in PDE6H causes autosomal-recessive incomplete achromatopsia. Am J Hum Genet 91: 527-532.
15. Yeh, CY, Goldstein, O, Kukekova, AV, Holley, D, Knollinger, AM, Huson, HJ et al. (2013). Genomic deletion of CNGB3 is identical by descent in multiple canine breeds and causes achromatopsia. BMC Genet 14: 27.
16. Sidjanin, DJ, Lowe, JK, McElwee, JL, Milne, BS, Phippen, TM, Sargan, DR et al. (2002). Canine CNGB3 mutations establish cone degeneration as orthologous to the human achromatopsia locus ACHM3. Hum Mol Genet 11: 1823-1833.
17. Pang, JJ, Alexander, J, Lei, B, Deng, W, Zhang, K, Li, Q et al. (2010). Achromatopsia as a potential candidate for gene therapy. Adv Exp Med Biol 664: 639-646.
18. Komáromy, AM, Alexander, JJ, Rowlan, JS, Garcia, MM, Chiodo, VA, Kaya, A et al. (2010). Gene therapy rescues cone function in congenital achromatopsia. Hum Mol Genet 19: 2581-2593.
19. Shamir, MH, Ofri, R, Bor, A, Brenner, O, Reicher, S, Obolensky, A et al. (2010). A novel day blindness in sheep: epidemiological, behavioural, electrophysiological and histopathological studies. Vet J 185: 130-137.
20. Reicher, S, Seroussi, E and Gootwine, E (2010). A mutation in gene CNGA3 is associated with day blindness in sheep. Genomics 95: 101-104.
21. Carvalho, LS, Xu, J, Pearson, RA, Smith, AJ, Bainbridge, JW, Morris, LM et al. (2011). Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy. Hum Mol Genet 20: 3161-3175.
22. Michalakis, S, Mühlfriedel, R, Tanimoto, N, Krishnamoorthy, V, Koch, S, Fischer, MD et al. (2010). Restoration of cone vision in the CNGA3-/-mouse model of congenital complete lack of cone photoreceptor function. Mol Ther 18: 2057-2063.
23. Michalakis, S, Mühlfriedel, R, Tanimoto, N, Krishnamoorthy, V, Koch, S, Fischer, MD et al. (2012). Gene therapy restores missing cone-mediated vision in the CNGA3-/-mouse model of achromatopsia. Adv Exp Med Biol 723: 183-189.
24. Pang, JJ, Deng, WT, Dai, X, Lei, B, Everhart, D, Umino, Y et al. (2012). AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia. PLoS One 7: e35250.
25. Alexander, JJ, Umino, Y, Everhart, D, Chang, B, Min, SH, Li, Q et al. (2007). Restoration of cone vision in a mouse model of achromatopsia. Nat Med 13: 685-687.
26. Mancuso, K, Hauswirth, WW, Li, Q, Connor, TB, Kuchenbecker, JA, Mauck, MC et al. (2009). Gene therapy for red-green colour blindness in adult primates. Nature 461: 784-787.
27. Shinozaki, A, Hosaka, Y, Imagawa, T and Uehara, M (2010). Topography of ganglion cells and photoreceptors in the sheep retina. J Comp Neurol 518: 2305-2315.
28. Hauswirth, WW, Aleman, TS, Kaushal, S, Cideciyan, AV, Schwartz, SB, Wang, L et al. (2008). Treatment of leber congenital amaurosis due to RPE65 mutations by ocular subretinal injection of adeno-associated virus gene vector: short-term results of a phase I trial. Hum Gene Ther 19: 979-990.
29. Acland, GM, Aguirre, GD, Ray, J, Zhang, Q, Aleman, TS, Cideciyan, AV et al. (2001). Gene therapy restores vision in a canine model of childhood blindness. Nat Genet 28: 92-95.
30. Acland, GM, Aguirre, GD, Bennett, J, Aleman, TS, Cideciyan, AV, Bennicelli, J et al. (2005). Long-term restoration of rod and cone vision by single dose rAAV-mediated gene transfer to the retina in a canine model of childhood blindness. Mol Ther 12: 1072-1082.
31. Narfström, K, Vaegan, Katz, M, Bragadottir, R, Rakoczy, EP and Seeliger, M (2005). Assessment of structure and function over a 3-year period after gene transfer in RPE65-/-dogs. Doc Ophthalmol 111: 39-48.
32. Mühlfriedel, R, Tanimoto, N and Seeliger, MW (2014). [Gene replacement therapy in achromatopsia type 2]. Klin Monbl Augenheilkd 231: 232-240.
33. Boye, SE, Boye, SL, Lewin, AS and Hauswirth, WW (2013). A comprehensive review of retinal gene therapy. Mol Ther 21: 509-519.
34. Cideciyan, AV (2010). Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res 29: 398-427.
35. MacLaren, RE, Groppe, M, Barnard, AR, Cottriall, CL, Tolmachova, T, Seymour, L et al. (2014). Retinal gene therapy in patients with choroideremia: initial findings from a phase clinical trial. Lancet 383: 1129-1137.
36. Sahel, JA and Roska, B (2013). Gene therapy for blindness. Annu Rev Neurosci 36: 467-488.
37. Komáromy, AM, Rowlan, JS, Corr, AT, Reinstein, SL, Boye, SL, Cooper, AE et al. (2013). Transient photoreceptor deconstruction by CNTF enhances rAAV-mediated cone functional rescue in late stage CNGB3-achromatopsia. Mol Ther 21: 1131-1141.
38. Sundaram, V, Wilde, C, Aboshiha, J, Cowing, J, Han, C, Langlo, CS et al. (2014). Retinal structure and function in achromatopsia: implications for gene therapy. Ophthalmology 121: 234-245.
39. Dubis, AM, Cooper, RF, Aboshiha, J, Langlo, CS, Sundaram, V, Liu, B et al. (2014). Genotype-dependent variability in residual cone structure in achromatopsia: Toward developing metrics for assessing cone health. Invest Ophthalmol Vis Sci 55: 7303-7311.
40. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N Engl J Med 358: 2240-2248.
41. Ezra-Elia, R, Banin, E, Honig, H, Rosov, A, Obolensky, A, Averbukh, E et al. (2014). Flicker cone function in normal and day blind sheep: A large animal model for human achromatopsia caused by CNGA3 mutation. Doc Ophthalmol 129: 141-150.
42. Polat, U (2008). Restoration of underdeveloped cortical functions: evidence from treatment of adult amblyopia. Restor Neurol Neurosci 26: 413-424.
43. Rizzo, S, Belting, C, Cinelli, L, Allegrini, L, Genovesi-Ebert, F, Barca, F et al. (2014). The Argus II Retinal Prosthesis: 12-month outcomes from a single-study center. Am J Ophthalmol 157: 1282-1290.
44. Renier, L, De Volder, AG and Rauschecker, JP (2014). Cortical plasticity and preserved function in early blindness. Neurosci Biobehav Rev 41: 53-63.
45. Cideciyan, AV, Hauswirth, WW, Aleman, TS, Kaushal, S, Schwartz, SB, Boye, SL et al. (2009). Vision 1 year after gene therapy for Leber's congenital amaurosis. N Engl J Med 361: 725-727.
46. Cideciyan, AV, Aguirre, GK, Jacobson, SG, Butt, OH, Schwartz, SB, Swider, M et al. (2015). Pseudo-fovea formation after gene therapy for RPE65-LCA. Invest Ophthalmol Vis Sci 56: 526-537.
47. Ashtari, M, Cyckowski, LL, Monroe, JF, Marshall, KA, Chung, DC, Auricchio, A et al. (2011). The human visual cortex responds to gene therapy-mediated recovery of retinal function. J Clin Invest 121: 2160-2168.
48. Ashtari, M, Cyckowski, L, Yazdi, A, Viands, A, Marshall, K, Bókkon, I et al. (2014). fMRI of retina-originated phosphenes experienced by patients with Leber congenital amaurosis. PLoS One 9: e86068.
49. Dilks, DD, Julian, JB, Peli, E and Kanwisher, N (2014). Reorganization of visual processing in age-related macular degeneration depends on foveal loss. Optom Vis Sci 91: e199-e206.
50. Palmer, S, Logan, D, Nabili, S and Dutton, GN (2010). Effective rehabilitation of reading by training in the technique of eccentric viewing: evaluation of a 4-year programme of service delivery. Br J Ophthalmol 94: 494-497.
51. Khan, NW, Wissinger, B, Kohl, S and Sieving, PA (2007). CNGB3 achromatopsia with progressive loss of residual cone function and impaired rod-mediated function. Invest Ophthalmol Vis Sci 48: 3864-3871.
52. Thiadens, AA, Roosing, S, Collin, RW, van Moll-Ramirez, N, van Lith-Verhoeven, JJ, van Schooneveld, MJ et al. (2010). Comprehensive analysis of the achromatopsia genes CNGA3 and CNGB3 in progressive cone dystrophy. Ophthalmology 117: 825-30. e1.
53. Genead, MA, Fishman, GA, Rha, J, Dubis, AM, Bonci, DM, Dubra, A et al. (2011). Photoreceptor structure and function in patients with congenital achromatopsia. Invest Ophthalmol Vis Sci 52: 7298-7308.
54. Fahim, AT, Khan, NW, Zahid, S, Schachar, IH, Branham, K, Kohl, S et al. (2013). Diagnostic fundus autofluorescence patterns in achromatopsia. Am J Ophthalmol 156: 1211-1219. e2.
55. Cassar, SC, Chen, J, Zhang, D and Gopalakrishnan, M (2004). Tissue specific expression of alternative splice forms of human cyclic nucleotide gated channel subunit CNGA3. Mol Vis 10: 808-813.
56. Dai, G, Sherpa, T and Varnum, MD (2014). Alternative splicing governs cone cyclic nucleotide-gated (CNG) channel sensitivity to regulation by phosphoinositides. J Biol Chem 289: 13680-13690.
57. Kaupp, UB and Seifert, R (2002). Cyclic nucleotide-gated ion channels. Physiol Rev 82: 769-824.
58. Biel, M and Michalakis, S (2007). Function and dysfunction of CNG channels: insights from channelopathies and mouse models. Mol Neurobiol 35: 266-277.
59. Ding, XQ, Harry, CS, Umino, Y, Matveev, AV, Fliesler, SJ and Barlow, RB (2009). Impaired cone function and cone degeneration resulting from CNGB3 deficiency: down-regulation of CNGA3 biosynthesis as a potential mechanism. Hum Mol Genet 18: 4770-4780.
60. Xu, J, Morris, L, Fliesler, SJ, Sherry, DM and Ding, XQ (2011). Early-onset, slow progression of cone photoreceptor dysfunction and degeneration in CNG channel subunit CNGB3 deficiency. Invest Ophthalmol Vis Sci 52: 3557-3566.
61. Nathans, J, Thomas, D and Hogness, DS (1986). Molecular genetics of human color vision: The genes encoding blue, green, and red pigments. Science 232: 193-202.
62. Wang, Y, Macke, JP, Merbs, SL, Zack, DJ, Klaunberg, B, Bennett, J et al. (1992). A locus control region adjacent to the human red and green visual pigment genes. Neuron 9: 429-440.
63. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167.